Deutsche Bank flagged patent expiries for Novo Nordisk while Medicare extended coverage for GLP-1 weight loss drugs.
1 report, 1 independent
Updated Jul 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Deutsche Bank flagged patent expiries for Novo Nordisk while Medicare extended coverage for GLP-1 weight loss drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Medicare prescription changes affect Novo Nordisk's revenue outlook, coinciding with a Deutsche Bank stock downgrade.Sub-event
Deutsche Bank warns about Novo Nordisk patent expiries; Medicare expands GLP-1 coverage.1 source
Keep exploring
The entities involved
-
Deutsche Bank
German global banking and financial services company
-
Novo Nordisk
Danish pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
- Novo Nordisk's Wegovy rollout is planned for Germany as GLP-1 therapies shift consumer priorities.
- Novo Nordisk launched insulin in the US market.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.